Cat. #151307
Anti-MUC2 [994/152]
Cat. #: 151307
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 3-4 weeks
Target: Mucin2 (MUC2)
Class: Monoclonal
Application: IHC ; ELISA ; IHC
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Lindy Durrant
Institute: University of Nottingham
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-MUC2 [994/152]
- Cancer: Digestive / Gastrointestinal cancer
- Cancers detailed: Broadly Applicable;Colorectal
- Research fields: Cancer;Cell biology;Cell signaling and signal transduction
- Clone: 994/152
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Reactivity: Human
- Host: Mouse
- Application: IHC ; ELISA ; IHC
- Description: Mucins are a family of highly glycosylated, large molecular weight glycoproteins which are associated with many epithelial cells. MUC2 is the major intestinal mucin. O-glycans are attached to MUC2 in a potentially diverse arrangement, which is crucial for their interaction with endogenous and exogenous lectins.
- Immunogen: A peptide based on the tandem repeat sequence of MUC2
- Isotype: IgG1
- Myeloma used: NS0
- Recommended controls: colon carcinoma
Target Details
- Target: Mucin2 (MUC2)
- Tissue cell line specificity: colon carcinoma
- Target background: Mucins are a family of highly glycosylated, large molecular weight glycoproteins which are associated with many epithelial cells. MUC2 is the major intestinal mucin. O-glycans are attached to MUC2 in a potentially diverse arrangement, which is crucial for their interaction with endogenous and exogenous lectins.
Applications
- Application: IHC ; ELISA ; IHC
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Dry ice
References
- Gold et al. 2013. Mol Cancer. 12(1):143. PMID: 24257318.
- Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin.
- Durrant et al. 1994. Eur J Cancer. 30A(3):355-63. PMID: 8204359.
- Production of monoclonal antibodies recognising the peptide core of MUC2 intestinal mucin.
